If you’re attending #SGIM24 this week, I’ll be at the poster session Thursday. Stop by! #diabetes #qualityimprovement

📢 Join me at #ADCES24, the essential event for diabetes care and education specialists! Don't miss out on early registration savings! Register by 6/20 and save. i.snoball.it/p/0LXd/t

Presented at #ERA24: FLOW trial: In patients with type 2 diabetes and chronic kidney disease, weekly semaglutide significantly reduced risks of major kidney events, cardiovascular events, and death from any cause while slowing loss of kidney function. nej.md/44U3slP

Amazing presentation on Day 1 of #ADA2024

An honor and a privilege to be on a panel American Diabetes Association - DiabetesPro discussing technology integration in primary care #ADA2024 #diabetestech #primarycare #diabeteseducation

Original Article: Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA) nej.md/4coe9zv Editorial: Entering a New Era in Sleep-Apnea Treatment nej.md/3RBd13I #ADASciSessions

It’s been wonderful to see the emphasis on diabetes care in primary care American Diabetes Association - DiabetesPro Scientific Sessions! Proud to contribute to this through our poster on “Building Capacity for Diabetes Primary Care via Endocrinology Telementoring” #ADA2024

It was an honor to receive a 2024 Be Exceptional award which recognized individuals & teams Boston Medical Center for their commitment to our mission & advancing our strategic goals. Im proud to be part of this incredible organization that is making a difference in the lives of our patients!

UConn School of Pharmacy Alumni and Friends reception in Boston for the American Association of Colleges of Pharmacy (AACP) 2024 Annual Meeting. It was great to get together with our faculty, alumni, and friends at this event. Go Huskies! #PharmEd24

Just in: Today we shared results from a Phase 3 study evaluating an investigational treatment for people living with heart failure with preserved ejection fraction (#HFpEF) and obesity. Read more about its potential impact: e.lilly/3AiSsmE

Did you know? Up to 40% of people living with #diabetes develop Chronic Kidney Disease #CKD. Early screening, timely diagnosis, and proper treatment are crucial to prevent severe complications and lower healthcare costs. Discover our key recommendations with Int. Diabetes Fed. ➡️

The main takeaway for all #healthcare providers is that people with #type1diabetes differ in important ways from those with type 2. And #T1D is more common in adults than you were probably taught. #diabetes medscape.com/viewarticle/wh…

Today, we shared results from a three-year study evaluating a potential treatment to reduce the risk of progression to type 2 diabetes in adults with pre-diabetes and obesity or overweight. e.lilly/4czWvJ5

We’re excited to share that the Omnipod® 5 Automated Insulin Delivery System is now indicated for adults with type 2 diabetes, ages 18+, making it the first and only AID system that is FDA-cleared for both type 1 & type 2 diabetes management. Learn more at omnipod.com/what-is-omnipo…

Exciting to see #diabetestech as OTC #Stelo Still have room to grow for equitable access with out of pocket cost, insurance coverage, and those without internet access to purchase online

If you are an MD, DO, NP, PA working in #primarycare and looking to earn #CEU #CME on #obesitymanagement , consider joinging this small group based learning I am leading.The Good Fight - Overcoming Challenges to Combat Obesity and Overweight 2024 provaeducation.gathered.com/invitation?ref…

We’re excited to announce that we’re partnering with Abbott and FreeStyle Libre to integrate the FreeStyle Libre 3 Plus sensor with the iLet Bionic Pancreas. Learn more: betabionics.com/beta-bionics-a…

In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin | Eli Lilly and Company Weekly basal insulin is promising in #type2diabetes investor.lilly.com/news-releases/…